CHINO HILLS, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC:SHMN) (the "Company"), a pharmaceutical, nutraceutical, cosmeceutical and biotech Company that manufactures and markets generic drugs covering numerous treatment categories, announces today the Company has filed a provisional patent application on its ABBIE "Smart Gene-Editing" platform that uses the latest enzymes and guide RNAs to resolve off-target gene-editing limitations.
Gene-editing Market
The gene-editing market was valued at $5.3 billion in 2023. The gene-editing market is expected to grow to $10.8 billion by 2028 with a 15% CAGR. (Source: 2023, Marketsandmarkets.com.)
"The U.S. FDA defines gene therapy as a treatment ‘to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use.' Gene therapy has become a critical tool for treating genetic diseases …," according to Life Sciences Intelligence.
The top five most expensive gene-editing therapies approved by the FDA are:
-- Hemgenix for hemophelia B ($3.5M / tx, approved Nov 2022)
-- Skysona for active cerebral adrenoleukodystrophy ($3M / tx, approved Sept 2022)
-- Zynteglo for beta-thalassemia ($2.8M / tx, approved Aug 2022)
-- Zolgensma for spinal muscular atrophy ($2.1M / tx, approved May 2019)
-- Luxturna for hereditary retinal dystrophy ($850,000 / eye, approved Dec 2017)
(Source: Life Sciences Intelligence, May 2023)
Drawbacks of Off-Target Edits
All effective gene therapies require a high level of control so that the gene-edits happen at precisely the intended site, and not "off-target" at unintended sites.
At any stage of the genomic edit, off-target edits in clinical settings can bear considerable consequences such as:
-- Tissue damage
-- Transformation of healthy cells into cancerous cells
The dangers above are amplified by the difficulty of detecting off-target edits which can lead to significant consequences for the administered gene-therapies, like those listed above.
The dangers and risks of off-target gene-edits are universal among leading gene-editing technologies including the likes of CRISPR.
All gene-editing technologies currently struggle with their lack of control and precision clinical applications (1).
ABBIE Resolves Off-target Edits and Improves Precision
ABBIE is resolving off-target edits by using the latest advances in:
-- Enzymes,
-- Guide RNA ...